Smith & Nephew Regulatory News (SN.)

Appointment of Marc Owen as Non-Executive Director

12 September 2017

Smith & Nephew (LSE: SN, NYSE: SNN), the global medical technology business, announces that Marc Owen is to join its Board as Non-Executive Director on 1 October 2017. He will also join the Audit Committee.

Marc Owen retired from Fortune 500 healthcare business McKesson Corp in March 2017 where he had served on the Executive Committee since 2001, holding a number of senior roles including Chairman of the Management Board of integrated pharmaceuticals services provider Celesio AG and President of the McKesson Speciality Health business. Marc Owen also worked for McKinsey for 12 years, specialising in healthcare and technology, and began his career as a barrister in London.

Roberto Quarta, Chairman of Smith & Nephew, commented:

"Marc Owen has proven himself as a leader with strategic vision who has built significant international healthcare businesses. Attracting such a strong candidate reflects well on the prospects for Smith & Nephew and ensures the Board maintains our deep commercial healthcare expertise when, as previously announced, Joe Papa retires at the Annual General Meeting next year."

Marc Owen is a British citizen and is 57 years old.

No disclosure obligations arise under paragraphs (1) to (6) of LR 9.6.13 R of the UK Listing Authority's Listing Rules in respect of this appointment. Marc Owen's fees will be $129,780 per annum of which $9,780 will be paid in the form of Smith & Nephew shares in-line with current Non-Executive Directors.

- ends -

 Enquiries

About Smith & Nephew

Smith & Nephew is a global medical technology business dedicated to helping healthcare professionals improve people's lives. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma & Extremities, Smith & Nephew has around 15,000 employees and a presence in more than 100 countries. Annual sales in 2016 were almost $4.7 billion. Smith & Nephew is a member of the FTSE 100 (LSE:SN, NYSE:SNN).

For more information about Smith & Nephew, please visit our website www.smith-nephew.com, follow @SmithNephewplc on Twitter or visit SmithNephewplc on Facebook.com.

Forward-looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew's expectations.

◊ Trademark of Smith & Nephew. Certain marks registered US Patent and Trademark Office.